INIS
International Isotopes Inc.0.0700
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
36.97MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
International Isotopes posted Q3 revenue of $3.3M, down 16% y/y from $3.9M on Theranostics supply outage, yet gross margin held at 59% versus 62%. YTD sales rose 2% y/y to $10.2M, driven by Calibration & Reference up 57% y/y, while operating loss widened to $181K from prior profit, reflecting higher salaries. Cash from operations fell to $210K YTD; $1.7M cash balances offset related-party notes due 2028 at 4-6%. Fluorine assets sale for $12.5M awaits NRC nod by March 2026. Supply disruptions threaten sales.
10-Q
Q2 FY2025 results
International Isotopes posted Q2 revenue of $3.7M, up 15% y/y from $3.2M, driven by Nuclear Medicine Standards surging 149% to $1.0M while Theranostics dipped 12%. Gross margin slipped to 59% from 64% amid higher costs, yielding a narrower operating loss of $135K versus $180K prior year; net loss tightened to $161K, with the gap to operating reflecting interest expense including Series C preferred dividends. Cash from operations hit $310K YTD, funding $190K capex for $121K FCF (derived); quarter-end cash stands at $1.9M, backed by $1.5M related-party notes payable (6%/4%, extended to 2028) and no revolver. Nuclear Medicine Standards now powers growth. Isotope supply disruptions loom large.
8-K
Shareholders approve key proposals
10-Q
Q1 FY2025 results
International Isotopes posted Q1 revenue of $3.2M, up 12% y/y from $2.9M, driven by Nuclear Medicine Standards surging 73% to $1.3M while Theranostics dipped 6% on supplier outage and Cobalt plunged 69% on timing. Gross margin held at 63%, but operating loss narrowed to $65K from $266K as expenses fell 2%; net loss shrank to $113K, with the gap to operating tied to interest expense including Series C preferred dividends. Cash fell to $1.6M amid operating use and note paydowns, yet covers 12 months. Medical Devices kicked off with $53K sales. Fluorine assets sale pends NRC nod. Isotope supply disruptions persist.
10-K
FY2024 results
International Isotopes hit record FY2024 revenues of $13.9 million, up 13% y/y, driven by Theranostics Products up 17% to $8.0 million and Cobalt Products surging 128% to $2.4 million, while Nuclear Medicine Standards dipped 20% to $3.5 million amid a cobalt-57 shortage. Q4 shone brightest: Nuclear Medicine Standards posted $1.4 million, its largest quarter ever, fueled by pent-up demand post-shortage. Gross margins expanded to 62% from 60%, flipping operating loss to slim profit of $6,901; net income $8,574. Cash from operations hit $639K. Q4 accelerated momentum. Supply disruptions threaten isotopes.
IPO
Website
Employees
Sector
Industry
ASPI
ASP Isotopes Inc.
5.69+0.00
BAX
Baxter International Inc.
19.05-0.48
IART
Integra LifeSciences Holdings C
13.00-0.47
IGPK
Integrated Cannabis Solutions,
0.00+0.00
IMCC
IM Cannabis Corp.
1.73+0.21
INCR
Intercure Ltd.
1.45+0.05
INM
InMed Pharmaceuticals Inc.
1.31+0.12
ISRG
Intuitive Surgical, Inc.
554.58-4.94
JNJ
Johnson & Johnson
209.30-4.87
ZTS
Zoetis Inc.
123.23+2.25